Market Overview

UPDATE: Jefferies Downgrades Infinity Pharmaceuticals to Hold on Limited Upside

Related INFI
Mid-Afternoon Market Update: Crude Oil Slides Over 2%; MannKind Shares Dip On Termination Of Afrezza Deal With Sanofi
Stocks Hitting 52-Week Lows
Combination Of Infinity Pharma And AbbVie Could Be A Big Winner For The Adventurous Stock Investor (Seeking Alpha)

Jefferies reduced its rating on Infinity Pharmaceuticals (NASDAQ: INFI) from Buy to Hold but raised its price target from $18 to $21.

Jefferies noted, "In the absence of positive events, INFI has gained significant traction on increased visibility of IPI-145 in Ph1/2a (its achievable potential yet-to-be defined; YTD +130% vs. +30% for NBI). While biotech valuation is often based on perceived potential for early-stage assets, at EV of ~$470M (vs. ~$490M for peers), with limited clinical data and numerous competitors in development, we view a Hold rating as appropriate for INFI.."

Infinity Pharmaceuticals closed at $20.20 on Tuesday.

Latest Ratings for INFI

Sep 2015Morgan StanleyUpgradesEqual-weightOverweight
May 2015Deutsche BankInitiates Coverage onBuy
Jan 2015Morgan StanleyDowngradesOverweightEqualweight

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings


Related Articles (INFI)

View Comments and Join the Discussion!

Get Benzinga's Newsletters